PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_948DAAE402FF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.
Journal
Cancer discovery
Author(s)
Tzeng S.F., Yu Y.R., Park J., von Renesse J., Hsiao H.W., Hsu C.H., Garnica J., Chen J., Chiu L.T., Santol J., Chen T.Y., Chung P.H., Kandalaft L.E., Starlinger P., Hsieh R.C., Yu M.C., Hsiao P.W., Carmona S.J., Chen H.K., Meng Z., Lin Y.H., Zhou J., Tsai C.H., Ho P.C.
ISSN
2159-8290 (Electronic)
ISSN-L
2159-8274
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.
OAI-PMH
oai:serval.unil.ch:BIB_948DAAE402FF
DOI
10.1158/2159-8290.CD-24-1409
Pubmed
40294022
Create date
02/05/2025 10:24
Last modification date
03/05/2025 7:09
Usage data